# Apatinib for Resectable Colorectal Cancer

> **NCT03228043** · NA · WITHDRAWN · sponsor: **Nanchong Central Hospital**

## Conditions studied

- Apatinib
- Outcome, Fatal
- Colorectal Cancer
- Surgery
- Adjuvant Chemotherapy

## Interventions

- **DRUG:** Apatinib
- **DRUG:** CAPEOX

## Key facts

- **NCT ID:** NCT03228043
- **Lead sponsor:** Nanchong Central Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-01
- **Primary completion:** 2021-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** It's not possible to complete in our hospital.
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03228043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03228043, "Apatinib for Resectable Colorectal Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03228043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*